# A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

> **NCT05211947** · PHASE3 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 1356 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Iclepertin

## Key facts

- **NCT ID:** NCT05211947
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-21
- **Primary completion:** 2025-02-26
- **Final completion:** 2025-03-18
- **Target enrollment:** 1356 (ACTUAL)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05211947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05211947, "A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05211947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*